GSK’s lung cancer drug receives US Breakthrough Therapy Designation
Drug gets US regulatory fast-trackSecond-phase trials planned for H2Significant need for new treatmentsGlobal biopharma company GSK (GSK) said it had received US Breakthrough Therapy Designation for its investigational antibody-drug...
20 August 2024